[1] |
PATEL JK, KITTLESON M, KOBASHIGAWA JA. Cardiac allograft rejection[J]. Surgeon, 2011, 9(3):160-167. DOI: 10.1016/j.surge.2010.11.023.
|
[2] |
COZZI E, COLPO A, DE SILVESTRO G. The mechanisms of rejection in solid organ transplantation[J]. Transfus Apher Sci, 2017, 56(4):498-505. DOI: 10.1016/j.transci.2017.07.005.
|
[3] |
HUSAIN AN, MIRZA KM, FEDSON SE. Routine C4d immunohistochemistry in cardiac allografts: long-term outcomes[J]. J Heart Lung Transplant, 2017, 36(12):1329-1335. DOI: 10.1016/j.healun.2017.09.004.
|
[4] |
KFOURY AG, HAMMOND ME, SNOW GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection[J]. J Heart Lung Transplant, 2009, 28(8):781-784. DOI: 10.1016/j.healun.2009.04.035.
|
[5] |
LOUPY A, TOQUET C, ROUVIER P, et al. Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection[J]. Am J Transplant, 2016, 16(1):111-120. DOI: 10.1111/ajt.13529.
|
[6] |
PEYSTER EG, MADABHUSHI A, MARGULIES KB. Advanced morphologic analysis for diagnosing allograft rejection: the case of cardiac transplant rejection[J]. Transplantation, 2018, 102(8):1230-1239. DOI: 10.1097/TP.0000000000002189.
|
[7] |
BRAZA MS, VAN LEENT MMT, LAMEIJER M, et al. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance[J]. Immunity, 2018, 49(5):819-828. DOI: 10.1016/j.immuni. 2018.09.008.
|
[8] |
MAGEE CN, MURAKAMI N, BORGES TJ, et al. Notch-1 inhibition promotes immune regulation in transplantation via regulatory T cell-dependent mechanisms[J]. Circulation, 2019, 140(10):846-863. DOI: 10.1161/CIRCULATIONAHA.119.040563.
|
[9] |
WU C, ZHAO Y, XIAO X, et al. Graft-infiltrating macrophages adopt an M2 phenotype and are inhibited by purinergic receptor P2X7 antagonist in chronic rejection[J]. Am J Transplant, 2016, 16(9):2563-2573. DOI: 10.1111/ajt.13808.
|
[10] |
ZHAO Y, CHEN S, LAN P, et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model[J]. Am J Transplant, 2018, 18(3):604-616. DOI: 10.1111/ajt.14543.
|
[11] |
ZHANG H, WU J, ZOU D, et al. Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade[J]. Am J Transplant, 2019, 19(3):884-893. DOI: 10.1111/ajt.15196.
|
[12] |
LIAO T, LIU X, REN J, et al. Noninvasive and quantitative measurement of C4d deposition for the diagnosis of antibody-mediated cardiac allograft rejection[J]. EBioMedicine, 2018, 37:236-245. DOI: 10.1016/j.ebiom. 2018.10.061.
|
[13] |
LIAO T, XUE Y, ZHAO D, et al. In vivo attenuation of antibody-mediated acute renal allograft rejection by ex vivo TGF-β-induced CD4+Foxp3+ regulatory T cells[J]. Front Immunol, 2017, 8:1334. DOI: 10.3389/fimmu.2017.01334.
|
[14] |
ZHAO D, LI S, LIAO T, et al. Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury[J]. Am J Transplant, 2018, 18(5):1083-1095. DOI: 10.1111/ajt.14602.
|
[15] |
ZHAO D, LIAO T, LI S, et al. Mouse model established by early renal transplantation after skin allograft sensitization mimics clinical antibody-mediated rejection[J]. Front Immunol, 2018, 9:1356. DOI: 10.3389/fimmu.2018.01356.
|
[16] |
COHEN D, COLVIN RB, DAHA MR, et al. Pros and cons for C4d as a biomarker[J]. Kidney Int, 2012, 81(7):628-639. DOI: 10.1038/ki.2011.497.
|
[17] |
COLVIN RB, SMITH RN. Antibody-mediatedorgan-allograft rejection[J]. Nat Rev Immunol, 2005, 5(10):807-817. doi: 10.1038/nri1702
|
[18] |
VALENZUELA NM, REED EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies[J]. J Clin Invest, 2017, 127(7):2492-2504. DOI: 10.1172/JCI90597.
|
[19] |
HAAS M. The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts[J]. Am J Transplant, 2018, 18(12):2849-2856. DOI: 10.1111/ajt.15088.
|
[20] |
COLVIN MM, COOK JL, CHANG P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association[J]. Circulation, 2015, 131(18):1608-1639. DOI: 10.1161/CIR.0000000000000093.
|
[21] |
JORDAN SC, AMMERMAN N, CHOI J, et al. Novel therapeutic approaches to allosensitization and antibody-mediated rejection[J]. Transplantation, 2019, 103(2):262-272. DOI: 10.1097/TP.0000000000002462.
|
[22] |
WU J, ZHANG H, SHI X, et al. Ablation of transcription factor IRF4 promotes transplant acceptance by driving allogenic CD4+ T cell dysfunction[J]. Immunity, 2017, 47(6):1114-1128. DOI: 10.1016/j.immuni.2017.11.003.
|
[23] |
BERRY GJ, BURKE MM, ANDERSEN C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis ofantibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 2013, 32(12):1147-1162. DOI: 10.1016/j.healun.2013.08.011.
|
[24] |
KAMAR N, ALLARD J, ADER JL, et al. Cyclosporine-A-based immunosuppression and renal functional reserve in organ-transplant patients[J]. Transplant Proc, 2004, 36(2 Suppl): 248S-250S. https://www.sciencedirect.com/science/article/abs/pii/S0041134503013514
|
[25] |
LIDDICOAT AM, LAVELLE EC. Modulation of innate immunity by cyclosporine A[J]. Biochem Pharmacol, 2019, 163:472-480. DOI: 10.1016/j.bcp.2019.03.022.
|